Company intelligence / Profile preview

Revlis Biotech

Taiwan

Ownership: Private
Development stage: Other

Overview

Revlis Biotech has deployed its CMATE/Tunstall Integrated Care Platform, providing remote ECG and chronic disease management devices and solutions; currently used with hospital partners and has achieved over 5 million cumulative ECG measurements and monitoring of 4 million+ symptoms.

Therapeutic areas: CardiovascularOther
Modalities: Device (ECG/health monitoring device)
Industry: Physiological Monitoring

Partnerships

Tunstall (UK, remote health services provider)Intel (IoT platform partnership for healthcare devices)

Beyond the preview

Go deeper on Revlis Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Revlis Biotech.

Explore the full profile